PT1017381E - Derivados de butirato no tratamento de fibromialgia e sindroma de fadiga cronica - Google Patents

Derivados de butirato no tratamento de fibromialgia e sindroma de fadiga cronica

Info

Publication number
PT1017381E
PT1017381E PT98941094T PT98941094T PT1017381E PT 1017381 E PT1017381 E PT 1017381E PT 98941094 T PT98941094 T PT 98941094T PT 98941094 T PT98941094 T PT 98941094T PT 1017381 E PT1017381 E PT 1017381E
Authority
PT
Portugal
Prior art keywords
syndrome
fibromyalgia
derivatives
chronic
butirato
Prior art date
Application number
PT98941094T
Other languages
English (en)
Inventor
Martin B Sharf
Original Assignee
Orphan Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphan Medical Inc filed Critical Orphan Medical Inc
Publication of PT1017381E publication Critical patent/PT1017381E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT98941094T 1997-08-29 1998-08-27 Derivados de butirato no tratamento de fibromialgia e sindroma de fadiga cronica PT1017381E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/920,979 US5990162A (en) 1997-08-29 1997-08-29 Method for treatment of fibromyalgia and chronic fatigue syndrome

Publications (1)

Publication Number Publication Date
PT1017381E true PT1017381E (pt) 2005-06-30

Family

ID=25444733

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98941094T PT1017381E (pt) 1997-08-29 1998-08-27 Derivados de butirato no tratamento de fibromialgia e sindroma de fadiga cronica

Country Status (14)

Country Link
US (1) US5990162A (pt)
EP (1) EP1017381B1 (pt)
JP (1) JP3660587B2 (pt)
AT (1) ATE289508T1 (pt)
AU (1) AU737086B2 (pt)
CA (1) CA2301723C (pt)
CZ (1) CZ295248B6 (pt)
DE (1) DE69829112T2 (pt)
ES (1) ES2235355T3 (pt)
IL (2) IL134669A0 (pt)
NO (1) NO326479B1 (pt)
NZ (1) NZ502983A (pt)
PT (1) PT1017381E (pt)
WO (1) WO1999009972A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140061T3 (da) * 1998-12-23 2003-08-25 Orphan Medical Inc Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
EP1316309A1 (en) * 1998-12-23 2003-06-04 Orphan Medical Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
ES2525553T3 (es) 1999-03-25 2014-12-26 Metabolix, Inc. Dispositivos y aplicaciones médicas de polímeros polihidroxialcanoato
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
US6623730B1 (en) * 1999-09-14 2003-09-23 Tepha, Inc. Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
US7553829B2 (en) * 2000-11-30 2009-06-30 Humanetics Corporation Treatment of chronic fatigue syndrome and fibromyalgia syndrome
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
US20100324441A1 (en) * 2002-02-04 2010-12-23 Hargrove Jeffrey B Brain-Related Chronic Pain Disorder Treatment Method and Apparatus
US6703216B2 (en) 2002-03-14 2004-03-09 The Regents Of The University Of California Methods, compositions and apparatuses for detection of gamma-hydroxybutyric acid (GHB)
EP2860292B1 (en) 2003-05-08 2020-07-22 Tepha, Inc. Polyhydroxyalkanoate medical textiles and fibers
ES2362217T3 (es) 2004-08-03 2011-06-29 Tepha, Inc. Suturas de polihidroxialcanoato no rizadas.
KR20070100686A (ko) * 2004-09-07 2007-10-11 오르펀 메디칼, 인크. 개선된 ｇｈｂ 조성물
MX2007005679A (es) * 2004-11-10 2007-07-11 Univ Columbia Metodo para tratamiento de desordenes de movimiento.
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
US7943683B2 (en) 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
JP4746714B2 (ja) * 2008-05-16 2011-08-10 Ａｘｉｓ株式会社 線維筋痛症治療用医薬組成物
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
CA2759251C (en) 2009-04-23 2017-01-03 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
CA2732479A1 (en) * 2011-02-14 2012-08-14 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
ES2804540T3 (es) 2011-02-14 2021-02-08 Concert Pharmaceuticals Inc Análogos deuterados de ácido 4–hidroxibutírico
US20160068463A1 (en) 2012-11-14 2016-03-10 Metabolix, Inc. Production of salts of 4-hydroxybutyrate using biobased raw materials
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
WO2016025329A1 (en) 2014-08-15 2016-02-18 Tepha, Inc. Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
EP3230500B1 (en) 2014-12-11 2025-06-18 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
US10682459B2 (en) 2014-12-22 2020-06-16 Sanofi-Aventis Deutschland Gmbh Drug delivery device with electromagnetic drive unit
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
FR3049463B1 (fr) 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3737353A1 (en) 2017-12-18 2020-11-18 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126216A1 (en) 2017-12-18 2019-06-27 Tris Phama, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337919B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
WO2022082105A2 (en) 2020-10-16 2022-04-21 Jazz Pharmaceuticals Ireland Limited Treatment methods using ghb
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2024163966A1 (en) 2023-02-03 2024-08-08 Tris Pharma, Inc. Low sodium oxybate once nightly composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60168044A (ja) * 1984-02-10 1985-08-31 Sharp Corp 感湿素子
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
JPH05262654A (ja) * 1992-03-18 1993-10-12 Kaken Pharmaceut Co Ltd 慢性疲労症候群治療剤
ITTO930510A1 (it) * 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) * 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin

Also Published As

Publication number Publication date
JP2001513552A (ja) 2001-09-04
DE69829112T2 (de) 2005-08-25
EP1017381B1 (en) 2005-02-23
JP3660587B2 (ja) 2005-06-15
CZ295248B6 (cs) 2005-06-15
NO20000989L (no) 2000-04-03
WO1999009972A1 (en) 1999-03-04
CA2301723A1 (en) 1999-03-04
AU8923798A (en) 1999-03-16
AU737086B2 (en) 2001-08-09
HK1029278A1 (en) 2001-03-30
ATE289508T1 (de) 2005-03-15
IL134669A0 (en) 2001-04-30
DE69829112D1 (de) 2005-03-31
US5990162A (en) 1999-11-23
CZ2000741A3 (cs) 2000-09-13
NO326479B1 (no) 2008-12-15
EP1017381A1 (en) 2000-07-12
CA2301723C (en) 2008-02-19
NO20000989D0 (no) 2000-02-28
ES2235355T3 (es) 2005-07-01
IL134669A (en) 2006-08-20
NZ502983A (en) 2001-08-31

Similar Documents

Publication Publication Date Title
PT1017381E (pt) Derivados de butirato no tratamento de fibromialgia e sindroma de fadiga cronica
ES2125233T3 (es) Tratamiento de las infecciones retrovirales humanas con 2',3'-didesoxiinosina.
BR9710536A (pt) Isobutilgaba e seus derivados para o tratamento da dor
BG100960A (bg) Дозирани форми с контролирано освобождаване на азитромицин
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
NO952469D0 (no) Terapautisk kombinasjon som inneholder interferon
FR2759581B1 (fr) Dispositif de traitement, notamment par moxa, de type acupressure
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
FI943142A7 (fi) Amidi- ja ureajohdannaiset, joilla on veren korkeita kolesteroliarvoja vastustava vaikutus, niiden valmistus ja terapeuttiset käytöt
EE9700302A (et) Meetod maania ja bipolaarse häire raviks
NO970533D0 (no) Blodbehandlingssystem og fremgangsmåte som overvåker citratretur til giveren
DK1291018T3 (da) Phosphonatananaloger til mannose-6phosphat og deres anvendelse i behandlingen af sår og fibrotiske lidelser
NO921223L (no) Kombinasjonspreparat med antitrombotisk virkning
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
NO894008L (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
PT984787E (pt) Utilizacao de heparinas de baixo peso molecular para a prevencao e o tratamento de edemas cerebrais
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
BR9708037A (pt) Método para o tratamento de abuso de substância
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
ZA9610073B (en) Method of using beta-interferons to treat restenosis
NO984198L (no) FremgangsmÕte for behandling av aggresjon
EA199800818A1 (ru) Способ лечения бессонницы
DE69106720D1 (de) Mentholderivate mit spasmolytik aktivität.